HIV‐1 Infection in Infants Severely Impairs the Immune Response Induced by Bacille Calmette‐Guérin Vaccine
Author(s) -
Nazma Mansoor,
Thomas J. Scriba,
Marwou de Kock,
Michèle Tameris,
Bernd Abel,
Alana Keyser,
Francesca Little,
Andreia Soares,
Sebastian Gelderbloem,
Silvia Mlenjeni,
Lea Denation,
Anthony Hawkridge,
W. Henry Boom,
Gilla Kaplan,
Gregory Hussey,
Willem A. Hanekom
Publication year - 2009
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/597304
Subject(s) - immunogenicity , medicine , vaccination , tuberculosis , immunology , immune system , bcg vaccine , virology , human immunodeficiency virus (hiv) , disease , pathology
Worldwide, most infants born to mothers infected with human immunodeficiency virus (HIV) receive bacille Calmette-Guérin (BCG) vaccine. Tuberculosis is a major cause of death among infants infected with HIV in sub-Saharan Africa, and it should be prevented. However, BCG may itself cause disease (known as "BCGosis") in these infants. Information regarding the immunogenicity of BCG is imperative for the risk/benefit assessment of BCG vaccination in HIV-infected infants; however, no such data exist.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom